Hyderabad based NATCO Pharma Limited has recorded consolidated total revenue of Rs. 2811.7 crore for the year ended on 31st March, 2023, as against Rs. 2043.8 crore for the last year, reflecting 37.6% growth. The net profit for the period, on a consolidated basis, was Rs. 715.3 crore, as against Rs. 170  crore last year.

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in ensuing years.

For the fourth quarter (Q4) ended March 31st, 2023, the company recorded a net revenue of Rs. 926.9 crore, on a consolidated basis, as against Rs. 610.6 crore during Q4, FY 2022. The profit for the fourth quarter, on a consolidated basis was Rs. 275.8 crore, as against a loss of Rs. 50.5 crore last year fourth quarter.